Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†-Reference-Cited by-同舟云学术

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

Published:2021-03 Issue:3 Volume:32 Page:309-322
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Dimopoulos M.A.,Moreau P.,Terpos E.,Mateos M.V.,Zweegman S.,Cook G.,Delforge M.,Hájek R.,Schjesvold F.,Cavo M.,Goldschmidt H.,Facon T.,Einsele H.,Boccadoro M.,San-Miguel J.,Sonneveld P.,Mey U.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference90 articles.

1. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project;Usmani;Blood Cancer J,2018

2. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Moreau;Ann Oncol,2017

3. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma;Kumar;Lancet Oncol,2016

4. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma;Perrot;Blood,2018

5. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis;Munshi;JAMA Oncol,2017

Cited by 423 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-life experience with first-line treatment with daratumumab, bortezomib, melphalan, and prednisone in patients with newly diagnosed multiple myeloma ineligible for autologous stem-cell transplantation;Frontiers in Hematology;2024-09-11

2. Changes in immune subsets during chemotherapy as prognosis biomarkers for multiple myeloma patients by longitudinal monitoring;Immunologic Research;2024-09-10

3. Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis;Hematology;2024-09-09

4. Lenalidomide or Thalidomide for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma? An Overview of Systematic Reviews;Value in Health Regional Issues;2024-09

5. Risk of Infection in Patients With Multiple Myeloma Treated With T-Cell Redirecting Approaches: A Call Out for Clinicians;Clinical Lymphoma Myeloma and Leukemia;2024-09